BridgeBio Pharma, Inc. (BBIO) › Operating IncomeBridgeBio Pharma, Inc. (BBIO) — Operating IncomeAnnual figures by period end, from SEC filings.2017-12-31: -$43.86M2018-12-31: -$183.66M2019-12-31: -$266.24M2020-12-31: -$474.48M2021-12-31: -$576.63M2022-12-31: -$512.20M2023-12-31: -$607.37M2024-12-31: -$592.97M2025-12-31: -$523.41M-$523.41M2017-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$523.41M—2026-02-24From 2025-01-012024-12-31-$592.97M—2026-02-24From 2024-01-012023-12-31-$607.37M—2026-02-24From 2023-01-012022-12-31-$512.20M—2025-02-20From 2022-01-012021-12-31-$576.63M—2024-02-22From 2021-01-012020-12-31-$474.48M—2023-02-23From 2020-01-012019-12-31-$266.24M—2022-02-25From 2019-01-012018-12-31-$183.66M—2021-02-25From 2018-01-012017-12-31-$43.86M—2020-03-03From 2017-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)